End-to-End Platform

The basis of Medigene’s differentiation is our end-to-end platform of multiple, combinable, exclusive and proprietary technologies. These technologies build in both the potential of enhancing our TCR-T drug products from a safety and / or efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.

Target
Screening

TCR
Generation

TCR-T Therapy Optimization

Manufacturing Scale-Up and Process Improvement

Clinical Development

Target
Screening

EXPItope-M

TCR
Generation

Allo-HLA TCR Priming
CrossTAg Vector System
JOVI Tag* Enrichment Technology
Robotic Functional HTS

TCR-T Therapy Optimization

PD1-41BB Switch
CD40L-CD28 Switch
Precision Pairing
Inducible iM-TCR

Manufacturing Scale-Up and Process Improvement

SIN-y- Retroviral Gene Transfer System
Cell Production Process & Quality Control
Drug Product Immune Assessment

Clinical Development

Patient Immune Monitoring
= Developmental Optimization Technology
= Efficacy Enhancement Technology
= Safety Enhancement Technology

EXPItope-M

Cross-reactivity of unwanted T cell response, among other things, due to the selection of non-suitable epitopes may result in elevated off-target effects and lethal toxicity. Therefore, identifying the proper target peptide HLA (pHLA) complex is crucial for generating TCRs for improved safety and efficacy. EXPItope-M, the refined version of EXPItope 2.0, is our improved proprietary tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues.

READ MORE

Allo-HLA TCR Priming

Immune tolerance, which is also known as central and peripheral tolerance, is the active state of unresponsiveness of the immune system to specific substances or tissues to prevent autoimmune diseases. The process of negative and positive selection play a significant role in the development of central tolerance, where the immune system learns to discriminate between self and non-self. Positive selection is the elimination of T cells lacking proper binding of the T- cell receptor (TCR) to the human leukocyte antigen (HLA). Conversely, negative selection eliminates high-affinity TCRs from the T cell repertoire with a very strong binding to any self-antigens, including cancer-testis antigens (CTAs), to avoid auto-immunity.

READ MORE

PD1-41BB Switch Receptor

Tumor immune escape (“Immune evasion”) is a phenomenon allowing cancer cells to proliferate and metastasize without being recognized by the host immune system. Immune evasion is one of the major challenges in immunotherapy.

READ MORE

Indicible iM-TCR

Persistent signaling can drive TCR-T cells to mediate inflammatory responses against vital tissues, especially in crucial organs like the brain. Moreover, over-activation or sustained TCR signaling can dampen the therapeutic efficacy leading to T cell exhaustion or cell death. One way to overcome persistent signaling is an inducible system to switch the TCR on and off selectively. Different approaches exist to control engineered T cells. Medigene merges its TCR with the 4OH-Tamoxifen inducible system, one of the best-characterized “reversible switch” models with numerous beneficial features.

READ MORE